EICHORCondition: Multiple Myeloma · Relapsed/Refractory Multiple Myeloma · Sponsor: C4 Therapeutics, Inc.
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
This description comes directly from the study's public registry record.
Study Medical Officer · (617) 231-0700 · clinicaltrials@c4therapeutics.com
Always discuss trial participation with your own doctor first.
| Clearview Cancer Institute | Huntsville, Alabama, United States | Recruiting |
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | Recruiting |
| HonorHealth | Scottsdale, Arizona, United States | Recruiting |
| Berenson Cancer Center | West Hollywood, California, United States | Recruiting |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
| Indiana University Health | Indianapolis, Indiana, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Mayo Clinic - Minnesota | Rochester, Minnesota, United States | Recruiting |
| Washington University/Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07284758